secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001193125-25-287163
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued
--------------------------------------------------------------------------------

- Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.
- Post-closing, existing TPST holders own ~35%; Erigen equityholders (Matt Angel and Lotus Capital) own ~38% and ~27% on fully diluted basis.
- Matt Angel appointed President & CEO; Stephen Brady becomes Chairman; Geoff Nichol resigns from board, effective at closing.
- Each TPST share to receive one warrant exercisable at $18.48 per share, valid for 5 years from issue date.
- Closing requires stockholder approval, Angel's appointment, and a minimum $5M pre-closing financing; expected early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/0001193125-25-287163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/d97617d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-287163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer